Jefferies Financial Group Inc. Acquires 89,000 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Jefferies Financial Group Inc. raised its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 41.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 305,600 shares of the company’s stock after buying an additional 89,000 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Harmony Biosciences were worth $10,516,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Hillsdale Investment Management Inc. lifted its stake in shares of Harmony Biosciences by 0.4% in the fourth quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company’s stock valued at $2,340,000 after buying an additional 300 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its stake in shares of Harmony Biosciences by 2.1% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company’s stock valued at $704,000 after buying an additional 420 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after purchasing an additional 436 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Harmony Biosciences by 28.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock valued at $80,000 after purchasing an additional 519 shares in the last quarter. Finally, Aviva PLC lifted its position in shares of Harmony Biosciences by 3.9% during the fourth quarter. Aviva PLC now owns 18,072 shares of the company’s stock valued at $622,000 after purchasing an additional 686 shares in the last quarter. 86.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HRMY. Deutsche Bank Aktiengesellschaft began coverage on shares of Harmony Biosciences in a research report on Tuesday, February 11th. They set a “buy” rating and a $55.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $49.00 price target on shares of Harmony Biosciences in a research report on Tuesday, May 6th. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. UBS Group dropped their price target on shares of Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a research report on Monday, April 28th. Finally, Mizuho raised their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a research report on Tuesday, March 18th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $52.33.

Harmony Biosciences Stock Performance

NASDAQ HRMY opened at $34.05 on Monday. Harmony Biosciences Holdings, Inc. has a 52-week low of $26.47 and a 52-week high of $41.61. The company has a 50-day simple moving average of $31.38 and a 200 day simple moving average of $34.01. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The company has a market capitalization of $1.96 billion, a PE ratio of 16.14, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. During the same quarter last year, the company posted $0.67 earnings per share. The firm’s quarterly revenue was up 19.5% compared to the same quarter last year. On average, research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.